Drugs / IP-QSV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07666750 | Jul 2026 → Aug 2027 expected | shigellosis | International Vaccine Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IP-QSV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07666750 ↗ |
| Modality | Vaccine | “a quadrivalent synthetic oligosaccharide-based Shigella vaccine (adjuvanted IP-QSV)” NCT07666750 ↗ |
| Route | Intramuscular | “for Intramuscular Administration” NCT07666750 ↗ |